EX-99.2
5
a11-28026_1ex99d2.htm
EX-99.2
Exhibit 99.2
Teva and Cephalon Receive European Commission Approval For Acquisition
Jerusalem, Israel and Frazer, PA, October 13, 2011
- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon Inc. (NASDAQ: CEPH) announced today that they received approval from the European Commission to proceed with Teva's acquisition of Cephalon.
In connection with this approval, Teva is required to divest Cephalon's marketing authorization of generic modafinil in France and grant to the purchaser of this marketing authorization certain additional rights with respect to the entire European Economic Area, including a covenant not to sue effective as of October 2012.
With this approval, the parties have now obtained all regulatory approvals required to close the transaction and, accordingly, have scheduled a closing date of October 14, 2011.
About Teva
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 42,000 people around the world and reached $16.1 billion in net sales in 2010.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic version of Protonix®, the extent to which any manufacturing or quality control problems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone® (including potential generic and oral competition for Copaxone®), the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of Cephalon), interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases
IR Contacts:
Elana Holzman
Teva Pharmaceutical Industries Ltd.
972 (3) 926-7554
Kevin C. Mannix
Teva North America
(215) 591-8912
PR Contacts:
Yossi Koren
Teva Pharmaceutical Industries Ltd.
972 (3) 926-7687
Denise Bradley
Teva North America
(215) 591-8974
in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in our Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.
# # #

EX - 99 . 2 5 a11 - 28026 _ 1ex99d2 . htm EX - 99 . 2 Exhibit 99 . 2 Teva and Cephalon Receive European Commission Approval For Acquisition Jerusalem , Israel and Frazer , PA , October 13 , 2011 - Teva Pharmaceutical Industries Ltd . ( NASDAQ : TEVA ) and Cephalon Inc . ( NASDAQ : CEPH ) announced today that they received approval from the European Commission to proceed with Teva 's acquisition of Cephalon . In connection with this approval , Teva is required to divest Cephalon 's marketing authorization of generic modafinil in France and grant to the purchaser of this marketing authorization certain additional rights with respect to the entire European Economic Area , including a covenant not to sue effective as of October 2012 . With this approval , the parties have now obtained all regulatory approvals required to close the transaction and , accordingly , have scheduled a closing date of October 14 , 2011 . About Teva Teva Pharmaceutical Industries Ltd . ( NASDAQ : TEVA ) is a leading global pharmaceutical company , committed to increasing access to high - quality healthcare by developing , producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients . Headquartered in Israel , Teva is the world 's largest generic drug maker , with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries . Teva 's branded businesses focus on neurological , respiratory and women 's health therapeutic areas as well as biologics . Teva currently employs approximately 42,000 people around the world and reached $ 16.1 billion in net sales in 2010 . Teva 's Safe Harbor Statement under the U . S . Private Securities Litigation Reform Act of 1995 : This release contains forward - looking statements , which express the current beliefs and expectations of management . Such statements are based on management 's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results , performance or achievements to differ significantly from the results , performance or achievements expressed or implied by such forward - looking statements . Important factors that could cause or contribute to such differences include risks relating to : our ability to successfully develop and commercialize additional pharmaceutical products , the introduction of competing generic equivalents , the extent to which we may obtain U . S . market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods , potential liability for sales of generic products prior to a final resolution of outstanding patent litigation , including that relating to the generic version of Protonix ® , the extent to which any manufacturing or quality control problems damage our reputation for high quality production , the effects of competition on sales of our innovative products , especially Copaxone ® ( including potential generic and oral competition for Copaxone ® ) , the impact of continuing consolidation of our distributors and customers , our ability to identify , consummate and successfully integrate acquisitions ( including the acquisition of Cephalon ) , interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes , intense competition in our specialty pharmaceutical businesses , any failures to comply with the complex Medicare and Medicaid reporting and payment obligations , our exposure to currency fluctuations and restrictions as well as credit risks , the effects of reforms in healthcare regulation , adverse effects of political or economical instability , major hostilities or acts of terrorism on our significant worldwide operations , increased government scrutiny in both the U . S . and Europe of our agreements with brand companies , dependence on the effectiveness of our patents and other protections for innovative products , our ability to achieve expected results through our innovative R & D efforts , the difficulty of predicting U . S . Food and Drug Administration , European Medicines Agency and other regulatory authority approvals , uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology - based products , potentially significant impairments of intangible assets and goodwill , potential increases IR Contacts : Elana Holzman Teva Pharmaceutical Industries Ltd . 972 ( 3 ) 926 - 7554 Kevin C . Mannix Teva North America ( 215 ) 591 - 8912 PR Contacts : Yossi Koren Teva Pharmaceutical Industries Ltd . 972 ( 3 ) 926 - 7687 Denise Bradley Teva North America ( 215 ) 591 - 8974 in tax liabilities resulting from challenges to our intercompany arrangements , our potential exposure to product liability claims to the extent not covered by insurance , the termination or expiration of governmental programs or tax benefits , current economic conditions , any failure to retain key personnel or to attract additional executive and managerial talent , environmental risks and other factors that are discussed in our Annual Report on Form 20 - F and other filings with the U . S . Securities and Exchange Commission . # # #